Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dicsol Plus Oil is a topical analgesic and anti-inflammatory formulation developed by Boffin Biotech for the localized relief of acute musculoskeletal pain, joint stiffness, sprains, strains, and arthritis. The formulation typically combines diclofenac diethylamine, methyl salicylate, menthol, and linseed oil. Diclofenac diethylamine acts as a non-steroidal anti-inflammatory drug (NSAID) by inhibiting cyclooxygenase (COX) enzymes to reduce pain-mediating prostaglandins. Methyl salicylate and menthol function as counterirritants that produce synergistic warming and cooling sensations to distract from deep muscle pain, while linseed oil enhances skin penetration and provides additional mild anti-inflammatory benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dicsol Plus Oil.